OBJECTIVES:  An increasing number of patients now take oral therapies to treat cancer, thereby highlighting the importance of patient preference and satisfaction with these therapies. As key outcomes in the oncology quality framework, there is a need to identify preference and satisfaction-related instruments in oral oncolytics and report their psychometric properties. METHODS:  A literature search was conducted according to PRISMA guidelines using PubMed database to identify relevant articles in English up until October, 2016. Non English studies, case reports and other review articles were excluded. Controlled search terminology included oral oncolytic therapy names in combination with satisfaction, preference and related terms. Psychometric properties of the instruments were extracted for qualitative synthesis. RESULTS:  Among 803 articles identified, 46 studies were included in the final review, of which, 18 had used validated instruments. The population ranged from 18 to 95 years and was being predominantly treated for breast and colorectal cancers. Most studies indicated that convenience and outcomes compared to intravenous drugs promoted the use of oral oncolytics whereas high cost and medication adherence were potential barriers influencing patient preference and satisfaction. A total of 15 standardized instruments (11 satisfaction and 4 preference) were reported. The most commonly used were Cancer Therapy Satisfaction Questionnaire (CTSQ) which evaluated 7 domains (expectations of cancer therapy, feelings about side effects, oral cancer therapy adherence, convenience, satisfaction with cancer therapy, stopping cancer therapy, and reasons for nonadherence) and Therapy Preference Questionnaire which evaluated 2 domains (characteristics interfering with daily activities and factors influencing treatment preference). These instruments also reported good psychometric properties. CONCLUSIONS:  Patient preference and satisfaction are crucial variables in medication adherence and are valuable when comparing treatments. With oral oncolytics being increasingly prescribed, it will be important to include validated preference and satisfaction instruments to document the changes in outcomes, thereby influencing treatment decisions in oncology care.